The poster presentation will include the rationale for the trial, study objectives, clinical trial design, and an update on accrual. The study will also evaluate pharmacokinetics, immune ...

"We are honored that our Trial in Progress poster has been accepted for presentation at ASCO 2025," said Anastasios Maniakas, MD, PhD, Assistant Professor in the Department of Head and Neck ...

Immutep (IMMP) announces an upcoming poster presentation for the TACTI-004 Phase III trial. The poster will be presented at the European Lung Cancer Congress, ELCC, 2025, taking place in Paris ...

Poster for GP2 Phase IIb clinical trial final efficacy analysis was ... San Antonio Breast Cancer Symposium Poster Presentation of Median 5 Year Top-Line Data The median 5 year top-line data ...

In addition, a trial-in-progress poster is also being presented to highlight the ongoing pivotal Phase 2 ALPHA3 trial, which is evaluating cemacabtagene ansegedleucel (cema-cel) as part of first ...

Flamingo has initiated a Phase II trial 'PEMDA-HN' evaluating the STAT3 targeting agent danvatirsen, in combination with pembrolizumab, in patients with head and neck squamous cell carcinoma (HNSCC).

Details on the company's poster presentation are below: Abstract Title: Phase 2 pilot trial of RRx-001 as an anti-mucositis agent in head and neck cancer patients treated with chemoradiation ...

The abstract contains data on selinexor monotherapy in a hard-to-treat, heavily pretreated myelofibrosis patient population from the Phase 2 XPORT-MF-035 trial. "We are encouraged by our new data ...